Business Context and Reporting Period
Company: Arrowhead Research Corporation (formerly InterActive Group, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Model: A development-stage nanotechnology company operating through three strategic components: an Outsourced R&D Program (funding university/government research), a Commercialization Program (majority-owned subsidiaries), and a Patent Toolbox. The company has no product sales revenue to date; revenue is derived from grants, development fees, and licensing.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2006 |
Six Months Ended Mar 31, 2006 |
Balance Sheet Mar 31, 2006 |
|---|---|---|---|
| Revenue | $57,500 | $310,000 | N/A |
| Operating Expenses | $4,002,650 | $8,307,882 | N/A |
| Net Loss | $(3,106,586) | $(6,243,538) | N/A |
| Cash & Cash Equivalents | N/A | N/A | $16,584,747 |
| Marketable Securities | N/A | N/A | $18,709,110 |
| Total Current Assets | N/A | N/A | $36,113,460 |
| Total Current Liabilities | N/A | N/A | $2,589,236 |
| Accumulated Deficit | N/A | N/A | $(15,722,648) |
Liquidity: The company holds approximately $35.3 million in cash and marketable securities. Management believes this is sufficient to fund operations beyond the end of fiscal year 2006.
Material Changes vs. Prior Period
- Net Loss Increase: The company reported a net loss of $3.1 million for the quarter ended March 31, 2006, compared to a net income of $615,930 for the same period in 2005. The prior year's income was significantly boosted by a one-time gain of $2.3 million from the sale of stock in a subsidiary (Insert Therapeutics).
- Expense Growth: Operating expenses increased significantly due to:
- Salaries: Increased by 148% (quarterly) due to hiring for Sarbanes-Oxley compliance, investor relations, and R&D staff.
- Stock-Based Compensation: Increased by 260% (quarterly) following the retrospective adoption of SFAS 123R.
- R&D Expenses: Increased by 159% (quarterly), driven by preclinical research, FDA filing costs for subsidiary Insert Therapeutics, and manufacturing of drug candidate IT-101 for Phase I trials.
- General & Administrative: Increased by 163% (quarterly) due to legal fees for capital raises and subsidiary recapitalization.
- Revenue: Revenue decreased slightly to $57,500 (quarterly) from $77,614 in the prior year, primarily due to the timing of grant and license fee recognition.
Guidance, Outlook, and Risks
- Outlook: The company does not expect any product sales revenue in fiscal year 2006. Losses are expected to increase as subsidiaries (Insert, Calando, Aonex) continue development and clinical trial preparations.
- Capital Commitments: Arrowhead has an agreement to provide up to $7 million in additional capital to subsidiary Calando Pharmaceuticals, contingent on achieving specific preclinical and clinical milestones.
- Recent Financing: In January 2006, the company completed a private placement raising approximately $19.6 million ($3.50/share) to fund working capital and subsidiary operations.
- Risks:
- Development Stage: No products are currently on the market; commercialization success is uncertain.
- Liquidity Dependence: Operations are funded by equity sales and grants; future funding may be required.
- Regulatory: Subsidiary Insert Therapeutics is awaiting Phase I clinical trial initiation; FDA approval is not guaranteed.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $35.3 million cash position against the projected $7 million commitment to Calando and ongoing high R&D burn rates.
- Subsidiary Milestones: Monitor the progress of Insert Therapeutics' Phase I clinical trials for IT-101 and Calando's RNAi therapeutic development, as these trigger capital commitments.
- Revenue Recognition: Confirm the timing and sustainability of revenue from the Benitec license agreement and SBIR grants, as these are the only current revenue sources.
- Dilution Risk: Review the impact of outstanding warrants (1.4 million shares) and stock options (4.4 million shares) on future share count.